WO2007084211A3 - Use of gpr54 ligands for treatment of reproductive disorders, proliferative disorders, and for contraception - Google Patents

Use of gpr54 ligands for treatment of reproductive disorders, proliferative disorders, and for contraception Download PDF

Info

Publication number
WO2007084211A3
WO2007084211A3 PCT/US2006/043975 US2006043975W WO2007084211A3 WO 2007084211 A3 WO2007084211 A3 WO 2007084211A3 US 2006043975 W US2006043975 W US 2006043975W WO 2007084211 A3 WO2007084211 A3 WO 2007084211A3
Authority
WO
WIPO (PCT)
Prior art keywords
gpr54
cancer
contraception
biological activity
disorders
Prior art date
Application number
PCT/US2006/043975
Other languages
French (fr)
Other versions
WO2007084211A2 (en
Inventor
William F Crowley Jr
Stephanie B Seminara
Tony M Plant
Ursula B Kaiser
Wendy Kuohung
Ross L Stein
Marcie Glicksman
Gregory D Cuny
Original Assignee
Gen Hospital Corp
Brigham & Womens Hospital
Univ Pittsburgh
William F Crowley Jr
Stephanie B Seminara
Tony M Plant
Ursula B Kaiser
Wendy Kuohung
Ross L Stein
Marcie Glicksman
Gregory D Cuny
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp, Brigham & Womens Hospital, Univ Pittsburgh, William F Crowley Jr, Stephanie B Seminara, Tony M Plant, Ursula B Kaiser, Wendy Kuohung, Ross L Stein, Marcie Glicksman, Gregory D Cuny filed Critical Gen Hospital Corp
Publication of WO2007084211A2 publication Critical patent/WO2007084211A2/en
Publication of WO2007084211A3 publication Critical patent/WO2007084211A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention features methods of treating a reproductive disorder such as central precocious puberty, polycystic ovarian disease, endometriosis, irregular periods, or uterine fibroids, a proliferative disorder involving a sex steroid dependent cancer such as a prostate cancer, breast cancer, uterine cancer, or testicular cancer, or ovarian cancer in a patient by administering an agonist of GPR54 or a compound that continuously interferes with a biological activity of a GPR54 polypeptide and decreases this biological activity or by administering a compound that continuously occupies a GPR54 polypeptide and decreases a biological activity of the GPR54 polypeptide. Such compounds may also be used in methods of contraception and in the preparation for in vitro fertilization.
PCT/US2006/043975 2005-11-11 2006-11-13 Use of gpr54 ligands for treatment of reproductive disorders, proliferative disorders, and for contraception WO2007084211A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US73569305P 2005-11-11 2005-11-11
US60/735,693 2005-11-11
US75781206P 2006-01-09 2006-01-09
US60/757,812 2006-01-09

Publications (2)

Publication Number Publication Date
WO2007084211A2 WO2007084211A2 (en) 2007-07-26
WO2007084211A3 true WO2007084211A3 (en) 2007-12-13

Family

ID=38288079

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/043975 WO2007084211A2 (en) 2005-11-11 2006-11-13 Use of gpr54 ligands for treatment of reproductive disorders, proliferative disorders, and for contraception

Country Status (1)

Country Link
WO (1) WO2007084211A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102209869B1 (en) 2017-12-12 2021-02-01 코스맥스 주식회사 Composition for anti-aging or anti-inflammation comprising kisspeptin

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060241051A1 (en) 2002-12-26 2006-10-26 Chieko Kitada Metastin derivatives and use thereof
US7754220B2 (en) 2003-03-12 2010-07-13 Takeda Pharmaceutical Company Limited Methods of inhibiting secretion of follicle-stimulating hormone and testosterone
RU2006145886A (en) 2004-06-25 2008-06-27 Такеда Фармасьютикал Компани Лимитед (Jp) DERIVATIVES METASTINE AND THEIR APPLICATION
US8404643B2 (en) 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
AR058584A1 (en) 2005-12-22 2008-02-13 Takeda Pharmaceutical METASTININE DERIVATIVES AND USE OF THE SAME
TWI404726B (en) 2006-10-25 2013-08-11 Takeda Pharmaceutical Metastin derivatives and use thereof
WO2009033748A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of osteostatin, alone or in combination with thymopentin, as a therapeutic agent
WO2009033780A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of growth hormone-releasing factor and/or k237 as a therapeutic agents
GB0719592D0 (en) 2007-10-08 2007-11-14 Medical Res Council Compound, use and method
EP2314609B1 (en) * 2008-07-30 2016-11-30 Takeda Pharmaceutical Company Limited Metastin derivative and use thereof
US8580294B2 (en) 2010-10-19 2013-11-12 International Partnership For Microbicides Platinum-catalyzed intravaginal rings
EP2825548A4 (en) * 2012-03-14 2016-02-24 Yeda Res & Dev Modified kisspeptin peptides and uses thereof
US10137031B2 (en) 2013-11-14 2018-11-27 International Partnership For Microbicides, Inc. Combination therapy intravaginal rings
TWI778979B (en) 2016-09-30 2022-10-01 瑞士商麥歐文科學有限公司 Methods of treating female infertility
CN110167522B (en) * 2017-12-12 2022-05-31 科丝美诗株式会社 Anti-aging or anti-inflammatory compositions comprising kisspeptin
JP2022534807A (en) * 2019-06-07 2022-08-03 ザ ジェネラル ホスピタル コーポレイション Kisspeptin for predicting and treating delayed puberty
RU2732688C1 (en) * 2020-02-06 2020-09-22 федеральное государственное бюджетное образовательное учреждение высшего образования "Курский государственный медицинский университет Министерства здравоохранения Российской Федерации Method of treating polycystic ovary syndrome with non-hormonal preparations
CN114822717A (en) * 2021-01-28 2022-07-29 腾讯科技（深圳）有限公司 Artificial intelligence-based drug molecule processing method, device, equipment and storage medium

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859295A (en) * 1994-12-05 1999-01-12 University Of Kentucky Research Foundation Canavanine analogs and their use as chemotherapeutic agents
US20050118290A1 (en) * 2003-12-02 2005-06-02 University Of Singapore Compositions and method for treatment of steroid/nuclear receptor-mediated diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859295A (en) * 1994-12-05 1999-01-12 University Of Kentucky Research Foundation Canavanine analogs and their use as chemotherapeutic agents
US20050118290A1 (en) * 2003-12-02 2005-06-02 University Of Singapore Compositions and method for treatment of steroid/nuclear receptor-mediated diseases

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BROWN ET AL.: "L-canavanine, an antigonadal substance for Dysdercus koenigii", ABSTRACT, ENTOMOLOGIA EXPER. ET APPLIC., vol. 34, no. 3, January 1983 (1983-01-01), pages 297 - 300, XP008091362 *
ENGSTROM ET AL.: "Prolactin Releasing Peptide has High Affinity and Efficacy at Neuropeptide FF2 Receptors", JOURNAL OF PHARM. AND EXPER. THERAPEUT., vol. 305, no. 3, 2003, pages 825 - 832, XP008092332 *
NAVARRO ET AL.: "Effects of KiSS-1 Peptide, the Natural Ligand of GPR54, on Follicle-Stimulating Hormone Secretion in the Rat", ENDOCRINOLOGY, vol. 146, no. 4, April 2005 (2005-04-01), pages 1689 - 1697, XP008091360 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102209869B1 (en) 2017-12-12 2021-02-01 코스맥스 주식회사 Composition for anti-aging or anti-inflammation comprising kisspeptin

Also Published As

Publication number Publication date
WO2007084211A2 (en) 2007-07-26

Similar Documents

Publication Publication Date Title
WO2007084211A3 (en) Use of gpr54 ligands for treatment of reproductive disorders, proliferative disorders, and for contraception
NZ608860A (en) Methods and reagents for treatment and diagnosis of age-related macular degeneration
MX2016011414A (en) Anti human interleukin-1 receptor accessory protein (il1 rap) antibodies and uses thereof.
MX2009000714A (en) Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof.
WO2008027837A3 (en) Small molecule potentiator of hormonal therapy for breast cancer
MX2020009512A (en) Combination therapy with targeted 4-1bb (cd137) agonists.
MX2017013565A (en) Selective androgen receptor degrader (sard) ligands and methods of use thereof.
EP2258382A3 (en) Amylin and amylin agonists for treating psychiatric diseases and disorders
TW200736277A (en) RANKL antibody-PTH/PTHrP chimeric molecules
EP2100618A3 (en) PDGFR-alpha antagonists for treatment of metastatic bone cancer
WO2010059969A8 (en) Use of anti-vegf antibody in combination with chemotherapy for treating breast cancer
MY185858A (en) Specific binding proteins and uses thereof
MX2009009146A (en) Methods and targets for identifying compounds for regulating rhinovirus infection.
MX2010005300A (en) 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroaryl pyrimidin-2-amines as janus kinase inhibitors.
JP2014503537A5 (en)
EP2985281A3 (en) Isoindoline compounds for use in the treatment of cancer
EP2481409A3 (en) Nanoparticle comprising rapamycin and albumin as anticancer agent
UA92490C2 (en) Imidazoquinolines as lipid kinase inhibitors
UA116187C2 (en) HETERO aryl substituted pyrrolo [2,3-b] Pyridines and pyrrolo [2,3-b] Pyrimidines as Janus kinase inhibitors
MX2007004551A (en) Thiadiazole compounds and methods of use.
EP3064509A3 (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
EP4306174A3 (en) Composition for controlled ovarian stimulation
TN2014000513A1 (en) Dual receptor antagonistic antigen-binding proteins and uses thereof
WO2015066053A8 (en) Targeted therapeutics
EP4219556A3 (en) Human monoclonal antibodies specific for flt3 and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06849329

Country of ref document: EP

Kind code of ref document: A2